ArticleInternational journal of clinical and experimental pathology2014
Immunological response of recombinant H. pylori multi-epitope vaccine with different vaccination strategies.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Immunoinformatics-Based Multi-Epitope Vaccine Targeting Helicobacter Pylori.Cancer reports (Hoboken, N.J.) · 2026Article
- UnravelingVaccines · 2025Review
- Immunoinformatics design and synthesis of a multi-epitope vaccine against Helicobacter pylori based on lipid nanoparticles.Scientific reports · 2024Article
- Review
- [Preparation and Release Properties ofSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021Article
- Pathogenesis and clinical management ofWorld journal of gastroenterology · 2019Review
- An engineered food-grade Lactococcus lactis strain for production and delivery of heat-labile enterotoxin B subunit to mucosal sites.BMC biotechnology · 2017Article
- Treatment of Helicobacter pylori infection: Current and future insights.World journal of clinical cases · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate different protective effects of recombinant H. pylori multi-epitope antigen (rIB) with cholera toxin subunit B (rCTB) as the intramolecular/extramolecular adjuvant though different immunization routes in a Helicobacter pylori infected mouse model.
methodsBy using rCTB as the intramolecular/extramolecular adjuvant of rIB, BALB/c mice were immunized through oral administration or intramuscular injection, on day 0, 14, 28. Every 14 days, ELISA was used to detect serum specific IgG and IgA titers after immunization. After the last immunization, H. pylori SS1 challenge was performed, and urease test, Gram staining after smearing of mouse gastric tissue, PCR, pathology and immunohistochemistry were used to evaluate preventive effect of the recombinant protein vaccine.
resultsAfter immunization three times, intramolecular injection could induce high titers of serum specific IgG antibody, and the antibody titer in rIB group, rCTB+rIB and rBIB group was 2000, 5000 and 7500, respectively (P < 0.05). Specific IgA antibody was only detected in rBIB oral administration group. The immune protection rate in rBIB oral administration group was significantly higher than that in rBIB intramolecular injection group (33.3% vs. 83%), indicating significant difference.
conclusionrCTB has good intramolecular/extramolecular immune adjuvant effects, and its intramolecular immune adjuvant effect is better. Both intramolecular injection and oral administration of rBIB have immune protective effect against H. pylori challenge, and oral administration of rBIB exerts better immune protective effect.
Indexed as
Identifiers
25400734PMC4230088W1745273139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.